Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS) issued its earnings results on Monday. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07, Briefing.com reports. The business had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.67) EPS.

Krystal Biotech Stock Down 3.1 %

Shares of KRYS opened at $170.85 on Tuesday. The company has a 50 day moving average of $182.28 and a two-hundred day moving average of $180.12. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $219.34. The company has a market cap of $4.91 billion, a price-to-earnings ratio of 46.81 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on KRYS shares. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. HC Wainwright lifted their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $196.75.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).